SG11201704500VA - Antibody binding to neuropilin 1 and use thereof - Google Patents
Antibody binding to neuropilin 1 and use thereofInfo
- Publication number
- SG11201704500VA SG11201704500VA SG11201704500VA SG11201704500VA SG11201704500VA SG 11201704500V A SG11201704500V A SG 11201704500VA SG 11201704500V A SG11201704500V A SG 11201704500VA SG 11201704500V A SG11201704500V A SG 11201704500VA SG 11201704500V A SG11201704500V A SG 11201704500VA
- Authority
- SG
- Singapore
- Prior art keywords
- neuropilin
- antibody binding
- antibody
- binding
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20140171949 | 2014-12-03 | ||
PCT/KR2015/013102 WO2016089126A1 (en) | 2014-12-03 | 2015-12-03 | Antibody against neuropilin 1 and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201704500VA true SG11201704500VA (en) | 2017-06-29 |
Family
ID=56092001
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201704500VA SG11201704500VA (en) | 2014-12-03 | 2015-12-03 | Antibody binding to neuropilin 1 and use thereof |
Country Status (9)
Country | Link |
---|---|
US (1) | US10364289B2 (en) |
EP (2) | EP3241844B1 (en) |
JP (1) | JP6475835B2 (en) |
KR (1) | KR101784451B1 (en) |
CN (1) | CN107108743B (en) |
AU (1) | AU2015355731B2 (en) |
CA (1) | CA2969402C (en) |
SG (1) | SG11201704500VA (en) |
WO (1) | WO2016089126A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3467508A4 (en) * | 2016-06-03 | 2020-04-29 | Samsung Life Public Welfare Foundation | Anti-nrp1 antibody screening method |
KR101985299B1 (en) * | 2016-06-03 | 2019-09-03 | 삼성전자주식회사 | Anti-c-Met/anti-Nrp1 bispecific antibody |
CN111133099B (en) * | 2017-08-23 | 2023-12-01 | 普罗赛拉治疗公司 | Use of neuropilin-1 (NRP 1) as a cell surface marker for isolation of human cardiac ventricular progenitor cells |
TW202126685A (en) * | 2019-09-24 | 2021-07-16 | 德商百靈佳殷格翰國際股份有限公司 | Anti-nrp1a antibodies and their uses for treating eye or ocular diseases |
CN113388586B (en) * | 2021-06-15 | 2024-01-02 | 广西医科大学 | Oncolytic virus NDV-NRP1 and construction method and application thereof |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
ATE87659T1 (en) | 1986-09-02 | 1993-04-15 | Enzon Lab Inc | BINDING MOLECULES WITH SINGLE POLYPEPTIDE CHAIN. |
FR2611064B1 (en) | 1987-02-13 | 1989-06-16 | Schvoerer Max | METHOD OF MARKING OBJECTS BY MICRO-CRYSTALS WITH MEMORY EFFECT AND MARKERS FOR IMPLEMENTING SAME |
SE456223B (en) | 1987-02-25 | 1988-09-19 | Sunds Defibrator | DISC REFINOR PAINTING ELEMENT |
DE3852304T3 (en) | 1987-03-02 | 1999-07-01 | Enzon Lab Inc | Organism as carrier for "Single Chain Antibody Domain (SCAD)". |
DE3884529T2 (en) | 1987-03-20 | 1994-04-28 | Creative Biomolecules Inc | LEADER SHARES FOR THE PRODUCTION OF RECOMBINANT PROTEINS. |
JPH02500876A (en) | 1987-03-20 | 1990-03-29 | クリエイティブ・バイオマリキュールズ・インコーポレーテッド | Recombinant polypeptide products and methods for their production, isolation and purification |
AU612370B2 (en) | 1987-05-21 | 1991-07-11 | Micromet Ag | Targeted multifunctional proteins |
WO1999029729A2 (en) | 1997-12-09 | 1999-06-17 | Children's Medical Center Corporation | Antagonists of neuropilin receptor function and use thereof |
WO2001036487A2 (en) | 1999-11-15 | 2001-05-25 | Miltenyi Biotec Inc. | Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby |
US7045283B2 (en) | 2000-10-18 | 2006-05-16 | The Regents Of The University Of California | Methods of high-throughput screening for internalizing antibodies |
EP1442749A1 (en) | 2003-01-31 | 2004-08-04 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of anti-CD100 antibodies for the treatment and the diagnosis of inflammatory disorder affecting the central nervous system |
US7906104B2 (en) * | 2005-08-04 | 2011-03-15 | The Regents Of The University Of California | Methods for detecting pancreatic beta-islet cells and diseases thereof |
AU2011253904B2 (en) * | 2005-11-08 | 2014-02-13 | Genentech, Inc. | Neuropilin antagonists |
UA96139C2 (en) * | 2005-11-08 | 2011-10-10 | Дженентек, Інк. | Anti-neuropilin-1 (nrp1) antibody |
EP2250278B1 (en) * | 2008-02-21 | 2023-04-05 | Burnham Institute for Medical Research | Methods and compositions related to peptides and proteins with c-terminal elements |
EP2445536B1 (en) | 2009-06-22 | 2016-06-08 | Burnham Institute for Medical Research | Methods and compositions using peptides and proteins with c-terminal elements |
KR20120106935A (en) * | 2009-07-13 | 2012-09-27 | 제넨테크, 인크. | Diagnostic methods and compositions for treatment of cancer |
WO2011143408A1 (en) * | 2010-05-13 | 2011-11-17 | Genentech, Inc. | Use of neuropilin-1 antagonists for the treatment of cancer |
RU2571226C2 (en) * | 2010-07-09 | 2015-12-20 | Дженентек, Инк. | Antibodies against neyropilin and methods of their application |
CN102161703A (en) * | 2010-12-30 | 2011-08-24 | 厦门大学 | Method for preparing monoclonal antibody resisting human neuropilin-1 |
TW201517916A (en) | 2013-03-15 | 2015-05-16 | Lilly Co Eli | Therapeutic uses for VEGFR1 antibodies |
JP6391676B2 (en) * | 2013-05-23 | 2018-09-19 | アジュ ユニバーシティー インダストリー−アカデミック コーオペレイション ファウンデーションAjou University Industry−Academic Cooperation Foundation | Tumor penetrating peptide specific for neuropilin and fusion protein fused with this peptide |
-
2015
- 2015-12-03 JP JP2017530040A patent/JP6475835B2/en active Active
- 2015-12-03 CN CN201580071971.8A patent/CN107108743B/en active Active
- 2015-12-03 CA CA2969402A patent/CA2969402C/en not_active Expired - Fee Related
- 2015-12-03 EP EP15865538.1A patent/EP3241844B1/en active Active
- 2015-12-03 WO PCT/KR2015/013102 patent/WO2016089126A1/en active Application Filing
- 2015-12-03 AU AU2015355731A patent/AU2015355731B2/en active Active
- 2015-12-03 SG SG11201704500VA patent/SG11201704500VA/en unknown
- 2015-12-03 KR KR1020150171139A patent/KR101784451B1/en active IP Right Grant
- 2015-12-03 EP EP20195622.4A patent/EP3783031B1/en active Active
- 2015-12-03 US US15/532,078 patent/US10364289B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US10364289B2 (en) | 2019-07-30 |
US20170291948A1 (en) | 2017-10-12 |
JP6475835B2 (en) | 2019-02-27 |
EP3783031A1 (en) | 2021-02-24 |
CN107108743B (en) | 2021-05-04 |
KR101784451B1 (en) | 2017-10-13 |
CA2969402C (en) | 2019-06-11 |
EP3241844B1 (en) | 2021-04-21 |
WO2016089126A1 (en) | 2016-06-09 |
CA2969402A1 (en) | 2016-06-09 |
CN107108743A (en) | 2017-08-29 |
EP3241844A4 (en) | 2018-09-05 |
JP2018503364A (en) | 2018-02-08 |
KR20160067767A (en) | 2016-06-14 |
EP3783031B1 (en) | 2023-08-02 |
EP3241844A1 (en) | 2017-11-08 |
AU2015355731B2 (en) | 2018-07-26 |
AU2015355731A1 (en) | 2017-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL288012A (en) | Antibody molecules to lag-3 and uses thereof | |
IL261188A (en) | Antibodies to tigit | |
IL266259A (en) | Antibodies to pd-1 and uses thereof | |
ZA201903848B (en) | Antibodies that specifically bind to human il-15 and uses thereof | |
ZA201808582B (en) | Antibodies to alpha-synuclein and uses thereof | |
GB201403875D0 (en) | Novel antibodies and uses thereof | |
GB201413913D0 (en) | Novel antibodies and uses thereof | |
ZA201905341B (en) | Antibodies specifically binding to human il-1r7 | |
IL247315B (en) | Anti-acth antibodies and use thereof | |
EP3262075C0 (en) | Novel antibody binding to tfpi and composition comprising the same | |
IL251676A0 (en) | Antibodies that bind to ccr6 and their uses | |
IL266516A (en) | Antibody binding specifically to cd66c and use thereof | |
IL269394A (en) | Antibodies binding to steap-1 | |
SG11201704500VA (en) | Antibody binding to neuropilin 1 and use thereof | |
PT3239177T (en) | Novel egfrviii antibody and composition comprising same | |
HK1245811A1 (en) | Antibodies that bind human c6 and uses thereof | |
PL3362480T3 (en) | Antibody specifically binding to erbb3 and use thereof |